Andrew G. Spencer, Ph.D.
Senior Vice President, Preclinical Research and Development
Dr. Andrew G. Spencer is an experienced research and development scientist who has contributed to programs from drug discovery into Phase 3 development. Since 2004, he has worked to develop new treatments for diseases in therapeutic areas including autoimmunity/inflammation, cardio-renal disease, and gastroenterology. Prior to joining Millendo, Dr. Spencer was vice president of pharmacology/DMPK at Ardelyx and a member of the senior management team. As program manager for the Ardelyx NHE3 inhibitor program, he made extensive contributions to the discovery and development of tenapanor and served as head of alliance management during partnerships with Sanofi and AstraZeneca. He served on multiple drug discovery project teams focused on discovery of new molecular entities and selection of compounds for clinical development. Before his time at Ardelyx, Dr. Spencer made significant early contributions to emerging treatments for celiac disease as a scientist at the Celiac Sprue Research Foundation and Alvine Pharmaceuticals. In addition, he worked on early drug discovery applications of siRNAs at Mirus Bio (now part of Arrowhead Research), and spent two years at humanized monoclonal antibody innovator PDL BioPharma.
Dr. Spencer holds a Ph.D. in biochemistry from Michigan State University and a B.S. in chemistry from Hope College. He completed a N.I.H. Postdoctoral Fellowship at the Howard Hughes Medical Institute at the University of Colorado at Boulder and in the Department of Biochemistry at the University of Wisconsin at Madison.